{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-004019","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.057895+00:00","generated_at":"2026-06-21T20:03:35.584614+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Chemomab appoints Matthew Frankel as CMO & VP Drug Development, effective Nov 14","bullets":["Dr. Frankel will receive annual base salary of $450,000 and bonus potential of 45% of base.","He receives a signing bonus of $200,000, payable in two $100,000 installments within 60 and 120 days.","Granted options to purchase 125,000 ADRs, vesting over four years (25% on first anniversary, remainder monthly).","Frankel previously led clinical development at Boehringer Ingelheim, Novartis, Sandoz, and Reata Pharmaceuticals.","Interim CMO Dave Weiner will stay on as Senior Advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-004019","json":"https://secwatch.observer/filing/0001178913-22-004019.json","markdown":"https://secwatch.observer/filing/0001178913-22-004019.md","text":"https://secwatch.observer/filing/0001178913-22-004019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/0001178913-22-004019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:03:35.584614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57bfd77207","claim":"Dr. Matthew B. Frankel was appointed as Chief Medical Officer & VP, Drug Development at Chemomab Therapeutics Ltd..","evidence_excerpt":"On November 14, 2022, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Matthew B. Frankel as Chief Medical Officer & VP, Drug Development of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/0001178913-22-004019-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer & VP, Drug Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}